BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 18250362)

  • 21. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
    Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
    Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
    Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
    Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
    Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
    Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
    Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
    Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.
    Wakino S; Hayashi K; Tatematsu S; Hasegawa K; Takamatsu I; Kanda T; Homma K; Yoshioka K; Sugano N; Saruta T
    Hypertens Res; 2005 Mar; 28(3):255-62. PubMed ID: 16097370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
    Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPARγ Activation.
    Elkahloun AG; Rodriguez Y; Alaiyed S; Wenzel E; Saavedra JM
    Mol Neurobiol; 2019 May; 56(5):3193-3210. PubMed ID: 30105672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence.
    Scalera F; Borlak J; Beckmann B; Martens-Lobenhoffer J; Thum T; Täger M; Bode-Böger SM
    Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1816-22. PubMed ID: 15308550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
    Song KH; Park JH; Jo I; Park JY; Seo J; Kim SA; Cho DH
    Vascul Pharmacol; 2016 Mar; 78():43-52. PubMed ID: 26455386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
    Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telmisartan increases the permeability of endothelial cells through zonula occludens-1.
    Bian C; Wu Y; Chen P
    Biol Pharm Bull; 2009 Mar; 32(3):416-20. PubMed ID: 19252288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.
    Li H; Lu W; Cai WW; Wang PJ; Zhang N; Yu CP; Wang DL; Liu BC; Sun W
    Pulm Pharmacol Ther; 2014 Jun; 28(1):17-24. PubMed ID: 24269521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway.
    Yuan Q; Peng J; Liu SY; Wang CJ; Xiang DX; Xiong XM; Hu CP; Li YJ
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):630-5. PubMed ID: 20132235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.
    Xuan H; Xu B; Wang W; Tanaka H; Fujimura N; Miyata M; Michie SA; Dalman RL
    J Vasc Surg; 2018 Feb; 67(2):573-584.e2. PubMed ID: 28434702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression.
    Wincewicz D; Juchniewicz A; Waszkiewicz N; Braszko JJ
    Pharmacol Biochem Behav; 2016 Sep; 148():108-18. PubMed ID: 27375198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.